<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03515707</url>
  </required_header>
  <id_info>
    <org_study_id>9784</org_study_id>
    <secondary_id>NCI-2017-02069</secondary_id>
    <secondary_id>9784</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT03515707</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia</brief_title>
  <official_title>Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well autologous stem cell transplant works in treating
      patients with favorable or intermediate risk, minimal residual disease (MRD)-negative, acute
      myeloid leukemia. Giving chemotherapy before a peripheral blood stem cell transplant helps
      kill any cancer cells that are in the body. After treatment, stem cells are collected from
      the patient's blood and stored. Higher dose chemotherapy is then given to prepare the bone
      marrow for the stem cell transplant. The stem cells are then returned to the patient to
      replace the blood-forming cells that were destroyed by the chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess the estimated probability of relapse at 2 years after autologous peripheral blood
      stem cell (PBSC) (ASCT) transplant.

      SECONDARY OBJECTIVES:

      I. Estimate the probability of transplant-related mortality (TRM) at 100 days following ASCT.

      II. Estimate probabilities of overall and disease-free survival. III. Assess if biological
      and molecular correlative studies can predict better outcome.

      OUTLINE:

      Patients receive targeted busulfan intravenously (IV) or oral (PO) every 6 hours on days -7
      to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on
      day 0.

      After completion of study treatment, patients are followed up yearly for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse</measure>
    <time_frame>Assessed up to 2 years post autologous stem cell transplant (ASCT)</time_frame>
    <description>Proportion of patients who relapse, as defined by 2017 NCCN AML guidelines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>From first dose of study therapy to day +100</time_frame>
    <description>Number of deaths without a prior relapse (unrelated to disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Assessed up to 4 years post-ASCT</time_frame>
    <description>Proportion of patients living without relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Assessed up to 4 years post-ASCT</time_frame>
    <description>Proportion of patients living with or without relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Minimal Residual Disease Negativity</condition>
  <arm_group>
    <arm_group_label>Treatment (busulfan, etoposide, ASCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV or oral every 6 hours on days -7 to -4 and etoposide IV on day -3. Patients then undergo autologous stem cell transplant on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo ASCT</description>
    <arm_group_label>Treatment (busulfan, etoposide, ASCT)</arm_group_label>
    <other_name>Autologous Hematopoietic Cell Transplantation</other_name>
    <other_name>Autologous Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV or oral</description>
    <arm_group_label>Treatment (busulfan, etoposide, ASCT)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (busulfan, etoposide, ASCT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (busulfan, etoposide, ASCT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML favorable or intermediate European LeukemiaNet (ELN) risk

          -  Achieved true 1st complete response (CR) (absolute neutrophil count [ANC] and platelet
             count &gt; 1,000/ul and 100,000/ul respectively) after first cycle of induction therapy,
             with no minimal residual disease (MRD)

          -  No measurable residual disease (MRD) as assessed by flow cytometry after initial
             induction therapy

          -  Performance score Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2

          -  Creatinine &lt; 2.0 mg/dl and calculated by Cockcroft-Gault (CG) formula or 24 hour
             measured creatinine clearance (CRCL) &gt; 50

          -  Not pregnant

          -  Received 1-2 courses of post remission &quot;consolidation&quot; therapy prior to mobilization
             PBSC

          -  No MRD by flow, cytogenics, FISH and molecular testing prior to collection of
             autologous PBSC collection

          -  Plan is to collect at least 3 x 10^6 CD34+ PBSC/kg cryopreserved. Preference is 4-5 X
             10^6 CD34 cells/kg.

        Exclusion Criteria:

          -  Life expectancy is severely limited by diseases other than AML

          -  Total bilirubin &gt; 2.0 mg/dl or serum glutamic-oxaloacetic transaminase (SGOT)/serum
             glutamate pyruvate transaminase (SGPT) &gt; 2.5 x upper limit of normal (ULN)

          -  History of Gilbert's disease

          -  Uncontrolled arrhythmias, left ventricular ejection fraction (LVEF) &lt; 50% or corrected
             diffusion capacity of the lung for carbon monoxide (DLCO) &lt; 50%

          -  Significant active infection that precludes transplant

          -  Hepatitis B or C viremia at time of ASCT

          -  History of central nervous system (CNS) involvement with AML
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona Holmberg</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leona A. Holmberg</last_name>
    </contact>
    <investigator>
      <last_name>Leona A. Holmberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2018</study_first_submitted>
  <study_first_submitted_qc>April 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2018</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

